Form 4: Black Diamond Therapeutics Director Acquires Shares in Lieu of Cash Compensation

A Black Diamond Therapeutics director, Prakash Raman, acquired 5,150 shares of common stock in lieu of cash compensation and disposed of 10,145 shares.

Summary

• Prakash Raman, a director at Black Diamond Therapeutics, acquired 5,150 shares of common stock on December 13, 2024.
• These shares were received in lieu of cash compensation for annual services as a non-employee director.
• The price of the shares was $2.5, based on the closing market price on December 12, 2024.
• The director also disposed of 10,145 shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction of a director receiving shares as compensation, with a disposal of shares. It is neither overwhelmingly positive nor negative.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Negatives

• The disposal of 10,145 shares by the director could be seen as a negative signal.

Risks

• Director share disposals can sometimes be interpreted negatively by the market.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders buy or sell shares. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• This type of transaction is common among publicly traded companies, where directors often receive stock as part of their compensation.
• The reporting of these transactions is mandated by the SEC to ensure transparency and prevent insider trading.
• Similar filings can be seen from directors of comparable biotech companies such as Xometry, Inc. and CRISPR Therapeutics.

Stakeholder Impact

• The share acquisition and disposal may have a minor impact on shareholder sentiment.

Key Dates

Keywords

Black Diamond Therapeutics, Director, Share Acquisition, Share Disposal, Compensation, BDTX, Prakash Raman